Discover the SERB selection of medications on Soin et Nature, designed to meet the specific needs of patients with rare conditions or those requiring intensive care, featuring formulations rigorously developed to ensure therapeutic efficacy and safety. This range includes essential treatments such as osmotic laxatives suitable for all ages, folic acid supplements to prevent deficiencies, and solutions for digestive disorders, thereby providing targeted and reliable medical support.
More detailsFounded in 1951, SERB Laboratories is a European pharmaceutical group specializing in the development, production, and distribution of medications for critical care, medical emergencies, and the management of rare diseases. The company, historically rooted in France, has undergone significant international expansion since the 2000s, enabling it to become a global player in the field of specialized pharmaceutical treatments.
SERB stands out for its expertise in complex therapeutic areas that are largely underserved by conventional medicine. Its portfolio includes specialty pharmaceuticals used in clinical toxicology, neurology, endocrinology, intensive care medicine, gastroenterology, and perinatal care. With a presence in more than 80 countries—including Europe, the Middle East, Australia, the United States, and Japan—SERB provides essential therapeutic solutions to patients whose needs are often considered unmet.
SERB focuses its activities on therapeutic segments with high medical value that are often neglected by the traditional pharmaceutical industry. These are primarily clinical areas where access to specific medications can be critical, even life-saving.
The company is particularly recognized for:
While SERB is recognized for its central role in specialized hospital settings, the company also develops solutions suitable for household medicine cabinets, addressing common conditions such as digestive disorders and nutritional deficiencies.
Importal is indicated for the symptomatic treatment of constipation. Formulated with lactitol, it works by increasing the water content of stools, facilitating their passage. It is available in three formulations tailored to different age groups: adults, children ages 7 and up, and infants from birth. Importal can also be used in the management ofhepatic encephalopathy by reducing the absorption of intestinal toxins.
Rocgel is analuminum oxide-based medication indicated forheartburn, acid reflux, and gastroesophageal reflux disease (GERD). By neutralizing stomach acid, it quickly relieves epigastric pain and the sensation of acid reflux. This medication should be taken separately from other oral medications to avoid interfering with their absorption.
Spéciafoldine is afolic acid-based medication, essential for the prevention of neural tube defects (NTDs) in women planning to become pregnant. The 0.4 mg dosage is recommended for primary prevention in women of childbearing age, while the 5 mg dosage is reserved for patients at increased risk (family history of NTDs, antiepileptic treatments, malnutrition, alcoholism, malabsorption disorders).
Toxicarb is an oral suspension of activated charcoal used as an emergency treatment for poisoning or drug overdose. Thanks to its strong adsorbing power, activated charcoal binds toxins in the gastrointestinal tract and prevents them from entering the systemic circulation. It can be administered to patients of all ages, including infants, using an adjusted dosage.
SERB is actively pursuing a global expansion strategy. Following the acquisition of Veriton Pharma in 2020, which strengthened its presence in neurology and rare diseases, the acquisition of BTG Specialty Pharmaceuticals in 2021 marked a decisive strategic milestone. This transaction enabled the company to:
Through a network of experienced distributors and a direct presence in several strategic regions, SERB ensures the availability of its medications in more than 80 countries, guaranteeing rapid access to essential treatments.
Beyond the clinical efficacy of its products, SERB makes it a point of honor to offer medications at carefully set prices, so they remain accessible to a greater number of patients, including those with chronic or long-term conditions. This ethical approach aims to minimize treatment interruptions due to cost, particularly for patients with rare diseases or conditions requiring long-term treatment.
The company also ensures compliance with European and international standards regarding quality, traceability, pharmacovigilance, and health safety.
SERB stands out for its unique positioning: it harnesses pharmaceutical technology to serve patients facing complex, rare, or urgent clinical situations. Whether addressing acute poisoning, digestive disorders, perinatal prevention, or intensive supportive care, SERB develops targeted solutions grounded in science, safety, and accessibility.
By expanding internationally and strengthening its portfolio through strategic acquisitions, SERB is cementing its role asa key global player in the field of essential medicines for patients with specific therapeutic needs.
